---
title: "Novoprotein: Nanjing Jinli and Suzhou Jinling plan to reduce their holdings of company shares by no more than 0.5180% and 0.5203%, respectively"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229408256.md"
description: "Novoprotein announced that shareholders Nanjing Jinli and Suzhou Jinling plan to reduce their holdings in the company through centralized bidding, block trading, and negotiated transfers due to their own funding needs. Nanjing Jinli intends to reduce its holdings by no more than 363,500 shares, with a planned reduction ratio of no more than 0.5180%. Suzhou Jinling intends to reduce its holdings by no more than 365,100 shares, with a planned reduction ratio of no more than 0.5203%. The reduction period is within three months starting from three trading days after the announcement is disclosed"
datetime: "2025-02-24T11:30:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229408256.md)
  - [en](https://longbridge.com/en/news/229408256.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229408256.md)
generator: "portal-rs"
---

# Novoprotein: Nanjing Jinli and Suzhou Jinling plan to reduce their holdings of company shares by no more than 0.5180% and 0.5203%, respectively

Novoprotein announced that shareholders Nanjing Jinli and Suzhou Jinling plan to reduce their holdings of the company's shares through centralized bidding, block trading, and inquiry transfer due to their own funding needs. Nanjing Jinli intends to reduce its holdings by no more than 363,500 shares, with a planned reduction ratio of no more than 0.5180%. Suzhou Jinling intends to reduce its holdings by no more than 365,100 shares, with a planned reduction ratio of no more than 0.5203%. The reduction period is within three months starting from three trading days after the announcement is disclosed

### Related Stocks

- [688137.CN](https://longbridge.com/en/quote/688137.CN.md)

## Related News & Research

- [Gold Rallies to 3-Month High](https://longbridge.com/en/news/296629959.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [IMMU: Vididencel delivers durable remissions in AML and CML, with broad late-stage clinical expansion](https://longbridge.com/en/news/296462827.md)
- [Exclusive-Israeli settler confronts Palestinian American at his besieged West Bank home](https://longbridge.com/en/news/296256809.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**